^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SYK inhibitor

    Related drugs:
    17d
    Inflammatory Signal Inhibitors for COVID-19 (MATIS) (clinicaltrials.gov)
    P1/2, N=185, Completed, Imperial College London | Recruiting --> Completed | N=456 --> 185
    Trial completion • Enrollment change
    |
    CRP (C-reactive protein)
    |
    Jakafi (ruxolitinib) • Tavalisse (fostamatinib)
    22d
    Network Controllability Reveals Key Mitigation Points for Tumor-Promoting Signaling in Tumor-Educated Platelets. (PubMed, Int J Mol Sci)
    A low-dose combination therapy of fostamatinib, Aducanumab, and acetylsalicylic acid (aspirin) may control TEP effects. In conclusion, our preclinical in silico approach revealed FDA-approved drugs that allow therapeutic targeting of metastasis-promoting TEPs and target NSCLC at the same time.
    Journal
    |
    SYK (Spleen tyrosine kinase) • FCGR2A (Fc fragment of IgG receptor IIa) • ITGA2B (Integrin Subunit Alpha 2b)
    |
    Tavalisse (fostamatinib) • aspirin
    24d
    Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=0, Withdrawn, National Heart, Lung, and Blood Institute (NHLBI) | N=20 --> 0 | Trial completion date: Dec 2028 --> Nov 2025 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Dec 2028 --> Nov 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Tavalisse (fostamatinib)
    1m
    Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=1, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Completed | N=20 --> 1 | Trial completion date: Apr 2026 --> Oct 2025 | Trial primary completion date: Apr 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Tavalisse (fostamatinib)
    3ms
    2018-523-00US1: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma (clinicaltrials.gov)
    P1, N=87, Terminated, Hutchmed | N=140 --> 87 | Trial completion date: Jan 2026 --> Mar 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2025; Study terminated by sponsor
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    sovleplenib (HMPL-523)
    3ms
    The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=0, Withdrawn, Hutchmed | N=48 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    sovleplenib (HMPL-523)
    3ms
    Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease (clinicaltrials.gov)
    P1, N=25, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial primary completion date: Aug 2025 --> May 2026
    Trial primary completion date
    |
    Tavalisse (fostamatinib)
    3ms
    NEK9-mediated Wnt signalling repressor TLE3 rewires Docetaxel resistance in cancer cells by inducing pyroptosis. (PubMed, Br J Cancer)
    Our study demonstrated that NEK9 plays an important role in Docetaxel resistance. The novel combination of NEK9 inhibitor Fostamatinib and Docetaxel needs further clinical investigation in advanced OSCC.
    Journal
    |
    TLE3 (TLE Family Member 3, Transcriptional Corepressor)
    |
    docetaxel • Tavalisse (fostamatinib)
    4ms
    A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults (clinicaltrials.gov)
    P2, N=320, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    5ms
    Effect of Syk Inhibitory Activity of Vialinin A on Degranulation from Antigen-Stimulated RBL-2H3 Cells. (PubMed, Biol Pharm Bull)
    Consequently, the phosphorylation of Syk downstream signalling proteins, such as linker for activation of T cells family and phospholipase Cγ1/2, essential in calcium ion mobilization and cell activation were slightly inhibited. These results suggest that vialinin A affects degranulation of RBL-2H3 cells by inhibiting Syk.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • SYK (Spleen tyrosine kinase) • USP5 (Ubiquitin Specific Peptidase 5)
    6ms
    Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Completed, Northwestern University | Active, not recruiting --> Completed
    Trial completion
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659)
    6ms
    FOSTA-ARDS: Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Inova Health Care Services | Initiation date: May 2025 --> Jul 2025
    Trial initiation date
    |
    Tavalisse (fostamatinib)